MD Anderson President Announces Retirement, Shares Leadership Transition Plans
The University of Texas (UT) MD Anderson Cancer Center is recognizing the leadership of President Peter WT Pisters, MD, following his announced plan to retire from MD Anderson to focus on the next chapter of his career. The UT System Board of Regents and Chancellor John M. Zerwas, MD, have named Jeffrey E. Lee, MD, Interim President, effective immediately. Dr. Pisters will work with Dr. Lee on a thoughtful transition through the end of September.
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology.
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,1 the Geriatric Assessment-Driven Intervention (GAIN) trial,2 the Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) study,3 and the Geriatric Intervention in Frail Older Patients With Cancer Receiving Chemotherapy (GERICO) trial,4 have consistently demonstrated that geriatric assessment–guided interventions can reduce treatment toxicity, improve communication and patient-centered care, and support treatment decision-making for older adults with cancer.
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1–positive advanced triple-negative breast cancer, according to an exploratory post hoc analysis of the phase III ASCENT-04/KEYNOTE-D19 trial1 presented at the 2026 ASCO Annual Meeting by Kevin Kalinsky, MD, MS, FASCO, Professor and Director in the Division of Medical Oncology and Co-Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University School of Medicine, Atlanta.
High-Risk Prostate Cancer: GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
From Results to Action: Leveraging Multidisciplinary Teams to Optimize NSCLC CareMore Top Stories
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Lori J. Pierce, MD, FASCO, Named Distinguished University Professor, University of Michigan
University of Michigan (U-M) Professor Lori J. Pierce, MD, is one of six U-M faculty members recognized for their outstanding teaching and service with one of the university’s prestigious honors, the Distinguished University Professorship. Lori J. Pierce, MD The U-M Board of Regents recently ...
Cancer Epidemiologist Joseph F. Fraumeni, Jr, MD, Dies at 93
The oncology community is mourning the loss of renowned physician-scientist and cancer epidemiologist Joseph F. Fraumeni, Jr, MD, who died on June 22, 2026, at the age of 93. During a career spanning more than 5 decades at the National Cancer Institute (NCI), Dr. Fraumeni fundamentally changed the...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
The first clinical evaluation of the chemotherapy-free combination of ifebemtinib and garsorasib showed encouraging antitumor activity in patients with previously treated KRAS G12C–mutated metastatic colorectal cancer, although the improvement in objective response rate over garsorasib alone did...
